mwb research downgrades Stratec stock to Sell

Published on 10/05/2026 at 13:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Stratec stock costs EUR 21.55 on October 5, 2026 after EUR 21.73. Second-quarter revenue rose 2.40 percent and margin reached 11.90 percent.

Flatlay mit Aktienzertifikat, ISIN-Karte, Probenfläschchen und medizinischen Utensilien — Stratec SE (DE000STRA555) wird symbolisiert durch dieses Flatlay mit Aktienzertifikat, ISIN-Karte und Laborutensilien, Illustration mit AI erstellt.

Stratec (ISIN DE000STRA555) was trading at EUR 21.55 at Lang & Schwarz on October 5, 2026 at 1:19 p.m. CEST, down 0.83 percent versus the prior close of EUR 21.73. The latest analyst signal came on September 17, 2026, when mwb research downgraded the stock from Hold to Sell while keeping its price target at EUR 21.00.

Analyst downgrade meets recovery risk

The downgrade followed Stratec's second-quarter 2026 performance. According to mwb research, currency-adjusted revenue increased 2.40 percent year over year and adjusted EBIT margin recovered to 11.90 percent in the quarter.

The same analysis puts the execution hurdle in the second half of 2026 at EUR 149.00 million to EUR 161.00 million of revenue. That range implies growth of 12.00 percent to 22.00 percent versus the second half of 2025, while customer ordering remains volatile.

Profitability improved in the second quarter

Boersengefluester.de reported that Stratec lifted EBIT from EUR 2.25 million to EUR 5.57 million in the second quarter of 2026, corresponding to an EBIT margin of 9.40 percent. The comparison matters because the company entered the year with weaker profitability in the first quarter.

The company told Boersengefluester.de that its 2026 outlook calls for currency-adjusted revenue growth in the mid-to-high single-digit percentage range and an adjusted EBIT margin of about 10.00 percent, excluding special factors. Its longer-term target is an adjusted EBIT margin of at least 13.00 percent by 2028 and at least 15.00 percent by 2030.

Next results date is November 12

Makkler lists November 12, 2026 as Stratec's next reporting date and gives a revenue estimate of EUR 59.00 million for that report. The date creates the next clear checkpoint for the recovery narrative, while the analyst downgrade keeps execution risk at the center of the valuation debate.

Stock remains below the analyst target

Stratec was valued at EUR 263.2 million on Xetra on October 2, 2026. The stock information page identifies Stratec as a medical technology company in the Pharma and Healthcare sector, with Xetra as its designated exchange and SBS as its symbol.

At EUR 21.55, the Lang & Schwarz quote stood EUR 0.55 above mwb research's EUR 21.00 target, while the daily move was minus 0.83 percent against the Lang & Schwarz prior close of EUR 21.73. For investors, the key balance is visible in the numbers: second-quarter margin recovery on one side and a demanding second-half revenue requirement on the other. The further course of trading is shown by the continuously updated real-time quote of Stratec stock.